Advances in Clinical and Experimental Medicine
2015, vol. 24, nr 4, July-August, p. 615–622
Publication type: original article
QT Interval Prolongation and QRS Voltage Reduction in Patients with Liver Cirrhosis
1 Department of Gastroenterology, Medical University of Lublin, Poland
2 Department of Cardiology, Medical University of Lublin, Poland
3 Student of the Second Faculty of Medicine, Medical University of Lublin, Poland
4 Independent Public Clinical Hospital No. 4 in Lublin, Poland
Background. Liver cirrhosis is associated with functional abnormalities of the cardiovascular system with coexisting electrocardiographic (ECG) abnormalities.
Objectives. The aim was to analyze ECG changes in patients with cirrhosis, to evaluate whether alcoholic etiology of cirrhosis and ascites has an impact on ECG changes.
Material and Methods. The study involved 81 patients with previously untreated alcoholic cirrhosis (64 patients with ascites, classes B and C according to the Child-Pugh classification; and 17 without ascites, categorized as class A); 41 patients with previously untreated cirrhosis due to chronic hepatitis C (HCV – 30 patients with ascites, classes B and C; and 11 without ascites, class A); 42 with alcoholic steatohepatitis and 46 with alcoholic steatosis. The control group consisted of 32 healthy volunteers. Twelve-lead ECG recordings were performed and selected parameters were measured.
Results. Significantly longer QT and QTc intervals and lower QRS voltage were found in patients with alcoholic and HCV cirrhosis compared to the controls. Significantly lower QRS voltage was found in subjects with ascites than in those without ascites. Removal of ascites significantly increased QRS voltage.
Conclusion. In cirrhosis, irrespective of etiology, ECG changes involved prolonged QT and QTc intervals and reduced QRS voltage. Prolonged QT and QTc intervals were not related to the severity of cirrhosis or to the presence of ascites. However, low QRS voltage was associated with the presence of ascites. Removal of ascites reverses low QRS voltage.
ascites, liver cirrhosis, electrocardiography, QT interval, QRS voltage.
- Moller S, Henriksen JH: Cardiovascular complications of cirrhosis. Gut 2008, 57, 268–278.
- Wong F: Cirrhotic cardiomyopathy. Hepatol Int 2009, 3, 294–304.
- Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F: Brain natriuretic peptide and severity of disesase in non-alcoholic cirrhosis patients. J Gastroenterol Hepatol 2005, 20, 1115–1120.
- Poliwczak AR, Białkowska J, Broncel M, Koziróg M, Dworniak K, Kotecka K, Jabłkowski M: Heart rhythm turbulence and NT-proBNP in decompensated liver cirrhosis – a pilot study. Med Sci Monit 2011, 17, 5–11.
- Saner FH, Neumann T, Canbay A, Treckmann JW, Hartmann M, Goerlinger K, Bertram S: High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011, 24, 425–432.
- Zardi EM, Abbate A, Zardi DM, Laffi G, Gensini GF, Romanoet SM: Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010, 56, 539–549.
- Alqahtani SA, Fouad TR, Lee SS: Cirrhotic cardiomyopathy. Semin Liver Dis 2008, 28, 59–69.
- Moller S, Henriksen JH: Cirrhotic cadiomyopathy. J Hepatol 2010, 53, 179–190.
- Shaikh S, Abro M, Qazi I, Yousfani A: Frequency of cirrhotic cardiomyopathy in patients with cirrhosis of liver: A tertiary care hospital evidence. Pak J Med Sci 2011, 27, 744–748.
- Moore AF, Hargest R, Martin M, Delicata RJ: Intra-abdominal hypertension and the abdominal compartment syndrome. Br J Surg 2004, 91, 1102–1110.
- Cuculi F, Jamshidi P, Kobza R, Rohacek M, Erne P: Precordial low voltage in patients with ascites. EP Europace 2008, 10, 96–98.
- Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, Caraceni P: QT interval in patients with noncirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003, 38, 461–467.
- Genovesi S, Prata Pizzala M, Pozzi M, Ratti L, Milanese M, Pieruzzi F, Vincenti A: QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci 2009, 116, 851–859.
- Lee RF, Glenn TK, Lee SS: Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007, 21, 125–140.
- Zambruni A, Trevisani F, Caraceni P, Bernardi M: Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006, 44, 994–1002.
- Firmansyah I, Hasan I, Lesmana LA, Alwi I, Rahardjo P: Prolonged QTc-interval in liver cirrhotic patient: prevalence and its relationship with severity of liver dysfunction. Indones J Gastroenterol Hepatol Dig Endoscopy 2004, 5, 1–6.
- Mozos I, Costea C, Serban C, Susan L: Factors associated with a prolonged QT interval in liver cirrhosis patients. J Electrocardiol 2011, 44, 105–108.
- Mimidis K, Papadopoulos V, Thomopoulos K, Tziakas D, Ritis K, Dalla V, Kotsiou S: Prolongation of the QTc interval in patients with cirrhosis. Ann Gastroenterol 2003, 16, 155–158.
- Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, Lenzi B: QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012, 32, 1510–1515.
- Herriksen JH, Gülberg V, Fuglsang S, Schifter S, Bendtsen F, GerbesAL, Møller S: Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scand J Clin Lab Invest 2007, 67, 643–653.
- Tarique S, Sarwar S: Correlation of prolonged QT interval and severity of cirrhosis of liver. Annals of KEMU 2011, 17, 103–107.
- Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S: Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005, 43, 637–644.
- Zambruni A, Trevisani F, Di Micoli A: Effect of chronic β-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008, 48, 415–421.
- Bal JS, Thuluvath PJ: Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003, 23, 243–248.
- Madias JE: Attenuation of ECG voltage in cirrhotic patients. Europace 2007, 3, 175–181.
- FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Med Watch 2011, www.fda.gov/Drugs/DrugSafety/ucm269086.htm.
- Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH: QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013, 346. DOI: http://dx.doi.org/10.1136/bmj.f288.
- Szponar J, Zapalska-Pożarowska K, Szponar E: Preventive treatment of prolongation of the QT interval. Przegl Lek 2012, 69, 535–540.
- Kramer DB, Zimetbaum PJ: Long-QT Syndrome. Cardiol Rev 2011, 19, 217–225.
- Vuppalanchi R, Juluri R, Ghabril M, Kim S, Thong N, Gorski JC, Chalasani N, Hall SD: Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 2011, 45, 638–642.
- Fazio G, Vernuccio F, Grutta G, Re GL: Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management. World J Cardiol 2013, 26, 5, 87–93.
- Chung EJ, Jeon YS, Kim HJ, Lee KH, Lee JW, Han KA, Jung SH: Torsade de pointes in liver transplantation recipient after induction of general anesthesia: a case report. Korean J Anesthesiol 2014, 66, 80–84.
- Di Micoli A, Zambruni A, Bracci E, Benazzi B, Zappoli P, Berzigotti A, Zoli M, Bernardi M, Trevisani F: “Torsade de pointes” during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. Dig Liver Dis 2009, 41, 535–538.